Evidence map›Paper›PMID 26093673›Full record

ArticleBMC infectious diseases2015

Trends in antibiotic resistance of Streptococcus pneumoniae and Haemophilus influenzae isolated from nasopharyngeal flora in children with acute otitis media in France before and after 13 valent pneumococcal conjugate vaccine introduction.

François Angoulvant, Robert Cohen, Catherine Doit, Annie Elbez, Andreas Werner, Stéphane Béchet, Stéphane Bonacorsi, Emmanuelle Varon, Corinne Levy

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06291012 (Evaluation of a Therapeutic Strategy to Reduce the Duration of Antibiotic Therapy for Community-acquired Alveolar Pneumonia in Children), which is not on this map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
4.8field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06291012 phase4not yet recruitingnot on this mapstarted 2024, after this paper: background citation

Evaluation of a Therapeutic Strategy to Reduce the Duration of Antibiotic Therapy for Community-acquired Alveolar Pneumonia in Children: a Randomized Controlled Non-inferiority Trial

TypeinterventionalSponsorUniversity Hospital, MontpellierRan2024 to 2027Enrolled1,100ConditionsCommunity-acquired Pneumonia, Child, OnlyArmsQuick response: Amoxicillin for 3 days, Delayed response: Amoxicillin for 5 days, Quick response: Amoxicillin for 5 days, Delayed response: Amoxicillin for 7 days
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Global Antimicrobial Non-Susceptibility Patterns ofInfection and drug resistance · 2026
    Review
  5. Review
  6. Immunization with recombinantExperimental biology and medicine (Maywood, N.J.) · 2024
    Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Current otorhinolaryngology reports · 2017
    Review
  19. Observational
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

François AngoulvantService d'Accueil des Urgences Pédiatriques, AP-HP, Hôpital Necker-Enfants-Malades, Université Paris Descartes Sorbonne Paris Cité, ECEVE - INSERM UMR1123, Paris, France. francois.angoulvant@nck.aphp.fr.
Robert CohenACTIV, Association Clinique et Thérapeutique Infantile du Val de Marne, Saint-Maur des Fossés, France. robert.cohen@wanadoo.fr.
Catherine DoitUniversité Paris Diderot Sorbonne Paris Cité, Paris, France. catherine.doit@rdb.aphp.fr.
Annie ElbezACTIV, Association Clinique et Thérapeutique Infantile du Val de Marne, Saint-Maur des Fossés, France. active@activ-france.fr.
Andreas WernerAFPA, Association Française de Pédiatrie Ambulatoire, Chambéry, France. docteur.werner.pediatre@wanadoo.fr.
Stéphane BéchetACTIV, Association Clinique et Thérapeutique Infantile du Val de Marne, Saint-Maur des Fossés, France. stephane.bechet@activfrance.fr.
Stéphane BonacorsiUniversité Paris Diderot Sorbonne Paris Cité, Paris, France. stephane.bonacorsi@rdb.aphp.fr.
Emmanuelle VaronNational Reference Center for Pneumococci, Laboratoire de Microbiologie, AP-HP, Hopital Européen Georges-Pompidou, Paris, France. emmanuelle.varon@egp.aphp.fr.
Corinne LevyACTIV, Association Clinique et Thérapeutique Infantile du Val de Marne, Saint-Maur des Fossés, France. corinne.levy@activ-france.fr.
Association Clinique et Thérapeutique Infantile du Val de Marne · FRAssistance Publique – Hôpitaux de Paris · FRAssociation Française de Pédiatrie Ambulatoire · FRSorbonne Paris Cité · FRUniversité Paris Cité · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAfter the implementation of pneumococcal conjugate vaccines (PCVs), the marked shift in Streptococcus pneumoniae (Pnc) serotype distribution led to a modification in pneumococcal antibiotic susceptibility. In 2011, the pattern of antibiotic prescription in France for acute otitis media in infants was greatly modified, with decreased use of third-generation cephalosporins and amoxicillin-clavulanate replaced by amoxicillin alone. To assess antibiotic strategies, here we measured the antibiotic susceptibility of Pnc and Haemophilus influenzae (Hi) isolated from nasopharyngeal flora in infants with acute otitis media in the 13-valent PCV (PCV13) era in France.

methodsFrom November 2006 to June 2013, 77 pediatricians obtained nasopharyngeal swabs from infants (6 to 24 months old) with acute otitis media. The swabs were sent for analysis to the national reference centre for pneumococci in France. Demographics, medical history, and physical examination findings were recorded.

resultsWe examined data for 7200 children, 3498 in the pre-PCV13 period (2006-2009) and 3702 in the post-PCV13 period (2010-2013). The Pnc carriage rate decreased from 57.9% to 54.2% between the 2 periods, and the proportion of pneumococcal strains with reduced susceptibility to penicillin or resistant to penicillin decreased from 47.1% to 39% (P < 0.0001). The Hi carriage rate increased from 48.2% to 52.4%, with the proportion of ß-lactamase-producing strains decreasing from 17.1% to 11.9% and the proportion of ß-lactamase-nonproducing, ampicillin-resistant strains remaining stable, from 7.7% to 8.2%. We did not identify any risk factor associated with carriage of ß-lactamase-producing Hi strains (such as daycare center attendance, otitis-prone condition or recent antibiotic use).

conclusionIn France, the nasopharyngeal carriage rate of reduced-susceptibility pneumococcal strains and ß-lactamase-producing Hi strains decreased in children with acute otitis media after 2010, the year the PCV13 was introduced. Accordingly, amoxicillin as the first-line drug for acute otitis media requiring antibiotics remains a valid choice.

Indexed as

Acute DiseaseAnti-Bacterial Agentsbeta-LactamasesChild, PreschoolDrug Resistance, MicrobialFemaleFranceHaemophilus influenzaeHumansInfantMaleNasopharynxOtitis MediaPneumococcal VaccinesStreptococcus pneumoniae13-valent pneumococcal vaccineAnti-Bacterial Agentsbeta-LactamasesPneumococcal Vaccines

Identifiers

PMID26093673
PMCPMC4475293
OpenAlexW1517655521

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.